Skip to content

To evaluate the efficacy and safety of endoscopic surgical system assisted thoracoscopic radical resection of esophageal cancer in clinical trials

To evaluate the efficacy and safety of endoscopic surgical system assisted thoracoscopic radical resection of esophageal cancer in clinical trials

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075849
Enrollment
Unknown
Registered
2023-09-18
Start date
2023-09-18
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Sponsors

Harbin Medical University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-75 years old, gender is not limited; (2) Definite diagnosis of malignant pathology; (3) The primary tumor was located in the middle and lower esophagus. Referring to the 8th TNM staging system of the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC), The cTNM stages were T1b-2, N0 and M0. (4) Be able to cooperate with and complete follow-up and related examinations; (5) Voluntarily participate in this experiment and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with severe cardiovascular and cerebrovascular diseases or serious heart, lung, liver, kidney and other major organ dysfunction, unable to tolerate anesthesia or surgical operations. (2) Patients with severe coagulation disorders. (3) Obese people (BMI> 40). (4) Severe and uncontrolled hypertension, diabetes, blood system disease, or immune system disease. (5) Combined with surgical site or systemic infection, severe inflammatory reaction. (6) Patients with ascites or ascites caused by esophageal cancer, with obvious signs of external invasion and perforation (such as hoarseness, coughing, etc.). (7) Pregnant, menstrual or breastfeeding women. (8) The ASA score is greater than grade II. (9) Patients with severe mental illness who cannot cooperate. (10) Participants in other investigational drug or device clinical trials have not been completed. (11) Patients considered unsuitable for participation in this project by the investigator.

Design outcomes

Primary

MeasureTime frame
Surgical non-conversion rate;

Secondary

MeasureTime frame
Number of lymph node dissection;Patient VAS score;Postoperative hospital stay;Surgeon satisfaction;

Countries

China

Contacts

Public ContactMa Jianqun

Harbin Medical University Cancer Hospital, 150 Haping Road, Nan'gang District, Harbin, Heilongjiang

Jianqunma@aliyun.com+86 133 5999 0466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026